Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.
about
Therapeutic cancer vaccines: past, present, and futureInhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrenceMultiple vaccinations: friend or foe.Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three casesVaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine.Cellular vaccine approachesAntigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.Boosting anticancer vaccines: Too much of a good thing?
P2860
Q26863283-A011EDFB-C96F-45AC-ACB9-DDF9A131F83CQ33903025-0381B6C1-70FA-4A91-8C29-FBAEB4F6B514Q34561877-1D5E9369-5F05-408B-A8B4-5A98DEE2B041Q34610121-3B6B8A7A-B221-4B0F-8FE8-F3FF28B59522Q34823085-C85FA7BC-1E0E-46EA-A5FC-05AFBEAFDAA8Q35203752-6CADC47A-899E-4DE6-BC8D-056FB4DBA348Q36198732-7638EFC0-38F6-4A86-91B1-9F8E67D71C1FQ36384615-7DB799CA-8D36-4411-9CBD-4F74F8DF38CDQ36555546-A7B61263-D5AC-40D0-BD26-BFCBD13DE270Q36734688-5CA8884F-6EA3-4F9E-BE23-F0D0A60F4FE0Q36827204-0079112B-8BA3-4D88-B2F5-5049FD2EC825Q36846646-28D20737-69EF-4C6E-B4E8-2C6CC8C68C83Q37014134-50236936-91A7-4026-B7C0-951E570C5A2CQ37297514-FB768632-8771-4CAB-9F73-56D3A0A30110Q37778690-79B3CFC7-B3C0-43BB-94AF-6E27B2D988A9Q37952804-827F99A5-7C55-434B-908C-1684F0107768Q38025094-B45EF83D-534D-4B75-8792-F6DCD539EE6AQ38293525-D1957AD3-DBBF-4688-BCFB-EF2B5DA830A6Q39300005-4110D086-C7AD-4E5F-ADD5-BC862DE2174EQ39564978-75324EDC-F9CF-4CAF-9B8E-2B5F83F10BDDQ42969735-6DEEC9F0-1D36-4A50-9565-F0D8688B6486
P2860
Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Partial CD4 depletion reduces ...... restores therapeutic efficacy.
@en
Partial CD4 depletion reduces ...... restores therapeutic efficacy.
@nl
type
label
Partial CD4 depletion reduces ...... restores therapeutic efficacy.
@en
Partial CD4 depletion reduces ...... restores therapeutic efficacy.
@nl
prefLabel
Partial CD4 depletion reduces ...... restores therapeutic efficacy.
@en
Partial CD4 depletion reduces ...... restores therapeutic efficacy.
@nl
P2860
P1476
Partial CD4 depletion reduces ...... restores therapeutic efficacy
@en
P2093
Bernard A Fox
Michael G LaCelle
P2860
P304
P356
10.1158/1078-0432.CCR-09-1113
P407
P577
2009-11-10T00:00:00Z